ProMetic Life Sciences Inc. (TSE:PLI)’s share price fell 3.6% during trading on Wednesday . The company traded as low as C$1.61 and last traded at C$1.62. 704,688 shares changed hands during trading, a decline of 29% from the average session volume of 998,701 shares. The stock had previously closed at C$1.68.

A number of brokerages recently commented on PLI. Cantor Fitzgerald restated an “overweight” rating on shares of ProMetic Life Sciences in a report on Monday, November 20th. National Bank Financial lowered their target price on ProMetic Life Sciences from C$2.50 to C$2.00 and set a “sector perform” rating for the company in a report on Wednesday, November 15th. Two equities research analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of C$3.50.

The firm has a market cap of $1,130.00, a P/E ratio of -9.35 and a beta of 2.39.

TRADEMARK VIOLATION WARNING: This report was originally published by Watch List News and is owned by of Watch List News. If you are viewing this report on another website, it was illegally stolen and republished in violation of US and international trademark & copyright laws. The original version of this report can be accessed at https://www.watchlistnews.com/prometic-life-sciences-pli-stock-price-down-3-6/1801796.html.

About ProMetic Life Sciences

Prometic Life Sciences Inc (ProMetic) is a Canada-based biopharmaceutical company. The Company has two segments: Small Molecule Therapeutics and Protein Technology. The Company offers its technology platform for large-scale drug purification of biologics, drug development, proteomics and the elimination of pathogens to various industries, and uses its own affinity technology that provides for extraction and purification of therapeutic proteins from human plasma in order to develop therapeutics and orphan drugs.

Receive News & Ratings for ProMetic Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ProMetic Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.